Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow up.
Corsini CA, Martins PFDS, Filgueiras PS, Lourenço AJ, Lima AES, Gomes SVC, Jeremias WJ, Alves PA, Fernandes GDR, Castro LLME, de Carvalho AT, Azevedo ACC, Curimbaba CAL, Lorencini DA, Junior EM, da Silva VM, Cervi MC, Borges MC, Nogueira ML, Campos GRF, Correa PRL, Carvalho TML, Dos Reis JGAC, Reis EVS, Castilho LDR, de Lima PR, do Nascimento JPR, de Oliveira JG, Filho OAM, Grenfell RFQE; Immunita team.
Corsini CA, et al. Among authors: correa prl.
Res Sq [Preprint]. 2024 Feb 29:rs.3.rs-3931021. doi: 10.21203/rs.3.rs-3931021/v1.
Res Sq. 2024.
PMID: 38464059
Free PMC article.
Preprint.